Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients.
Irit AviviTamir ShragaiEfrat LuttwakSvetlana TrestmanYael C CohenPublished in: European journal of haematology (2023)
Low-dose B-MAF regimen showed high-efficacy and low-toxicity profile.